ClinicalTrials.Veeva
Menu

Find clinical trials for Pancreatic Cancer in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Adenocarcinoma
Cancer
Carcinoma
Colorectal Cancer
Non-Small-Cell Lung Carcinoma
Lung Cancer
Squamous Cell Carcinoma of Head and Neck

Pancreatic Cancer trials near Barcelona, CT, ESP:

Olaparib and Durvalumab (MEDI4736) in Patients With Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations

Patients with metastatic pancreatic cancer and germline mutation in BRCA have benefit of therapy with PARP inhibitors. In addition,...

Enrolling
Metastatic Pancreatic Cancer
Drug: olaparib+durvalumab

Phase 2

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Barcelona, Spain and 2 other locations

with either gemcitabine plus nab-paclitaxel (G/NP) or FOLFIRINOX in the treatment of participants with locally advanced, unresectable pancreatic...

Active, not recruiting
Pancreatic Cancer Non-resectable
Drug: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
Drug: Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX

Phase 3

FibroGen
FibroGen

Barcelona, Spain and 89 other locations

Randomized, Open-Label Clinical Study of GB201 in Combination with Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Metastatic Pancreatic...

Enrolling
Metastatic Pancreatic Cancer
Other: Standard of care treatment options
Drug: GB201

Phase 2, Phase 3

1Globe Health Institute

Barcelona, Spain and 37 other locations

A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer...

Enrolling
Pancreatic Adenocarcinoma
Metastatic
Genetic: VCN-01
Drug: Gemcitabine

Phase 2

Theriva Biologics

Barcelona, Spain and 16 other locations

SOT102 administered as monotherapy (Part C) and in combination with first-line SoC treatment (Part D) in patients with advanced or metastatic pancreatic...

Enrolling
Pancreatic Cancer
Drug: SOT102

Phase 1, Phase 2

SOTIO
SOTIO

Barcelona, Spain and 7 other locations

In order to improve the survival rates and decrease progression of pancreatic advanced cancer, this study aims to evaluate the firs...

Active, not recruiting
Pancreatic Ductal Adenocarcinoma
Drug: Nab paclitaxel
Drug: Zalifrelimab

Phase 1, Phase 2

Nelum

Barcelona, Cataluña, Spain and 5 other locations

regimen gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer who are treatment-naïve in the advanced disease se...

Enrolling
Metastatic Pancreatic Cancer
Drug: OMO-103
Drug: Nab-Paclitaxel

Phase 1

Peptomyc

Barcelona, Spain and 3 other locations

treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC).Two cohorts will be enrolled in parallel in t...

Active, not recruiting
Pancreatic Adenocarcinoma
Drug: Fluorouracil
Drug: RO6874281

Phase 1, Phase 2

Roche
Roche

Barcelona, Spain and 26 other locations

Phase 1b/2 study to assess the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic du...

Enrolling
Metastatic Pancreatic Ductal Adenocarcinoma
Biological: CD40 agonist mitazalimab in combination with chemotherapy

Phase 1, Phase 2

Alligator Bioscience

Barcelona, Spain and 15 other locations

or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have recei...

Enrolling
Pancreatic Cancer Metastatic
Pancreatic Cancer Stage IV
Drug: Gemcitabine
Drug: Nab-paclitaxel

Phase 2, Phase 3

Panbela Therapeutics

Barcelona, Spain and 91 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems